Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05074940 · OUTCOME

Overall Response Rate Measured by RECIST Criteria

Amivantamab in Adenoid Cystic Carcinoma · Source last updated 2026-05-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
2 years

What was measured

To determine the overall response rate in patients with recurrent and metastatic adenoid cystic carcinoma treated with amivantamab. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR."

Analysis population: 3 patients were unevaluable and excluded from efficacy analyses for discontinuing amivantamab treatment before first restaging. Thus, 18 subjects were included for analyses.

Groups in this outcome

Amivantamab

Amivantamab weekly for the first cycle and biweekly thereafter. Amivantamab: Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Amivantamab18

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Amivantamab1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      18
    units
    Participants
description
To determine the overall response rate in patients with recurrent and metastatic adenoid cystic carcinoma treated with amivantamab. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR."
groups
  1. description
    Amivantamab weekly for the first cycle and biweekly thereafter. Amivantamab: Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).
    id
    OG000
    title
    Amivantamab
param Type
COUNT_OF_PARTICIPANTS
population Description
3 patients were unevaluable and excluded from efficacy analyses for discontinuing amivantamab treatment before first restaging. Thus, 18 subjects were included for analyses.
reporting Status
POSTED
time Frame
2 years
title
Overall Response Rate Measured by RECIST Criteria
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice